MET and non-small cell lung carcinoma: Another example was tepotinib (EMD 1214063), which showed promising activity in NSCLC patients harboring c-MET exon14 skipping mutations with an ORR of 60% (9/15) [34], while cabozantinib alone or combined with erlotinib has superior efficacy to that of erlotinib alone in patients with wild-type EGFR NSCLC [29].